Download Free Medical Specialty Pharmacy and Biosimilars PowerPoint Presentation

Specialty Pharmacy and Biosimilars PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This presentation on Specialty Pharmacy and Biosimilars was created by the School of Pharmacy Relations Committee for AMCP. This presentation tries to obtain an understanding of specialty pharmaceuticals, understand the challenges of specialty pharmaceuticals for managed care companies, describe the value that specialty products bring to the market and Biosimilars.

Tags : Managed Care Pharmacy, healthcare, Academy of Managed Care Pharmacy, pharmacists, Managed Care Organizations, Student Pharmacist, Medication Therapy Management, Part D, Prescription Drug, Biosimilars, Specialty Pharmacy, specialty pharmaceuticals

Published on : Jul 01, 2020 | Views : 2609 | Downloads : 1

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Specialty Pharmacy and Biosimilars Created by the School of Pharmacy Relations Committee for AMCP Updated: January 2020
Slide 2-

Part 1: Specialty Pharmacy
Slide 3-

Objectives Obtain an understanding of specialty pharmaceuticals Understand the challenges of specialty pharmaceuticals for managed care companies Describe the value that specialty products bring to the market
Slide 4-

Definition of Specialty Pharmaceuticals Lack of universal definition “Biologic, biological, biopharmaceutical, biotech” Can include high cost injectable, infused product, oral agent or inhaled medication May require close supervision, monitoring and handling requirements Medicare’s Part D definition for specialty: any drug for which the negotiated monthly price is $600 or more Can be administered at home, MD office, infusion center or outpatient hospital
Slide 5-

Impact of Specialty Products Specialty drugs have been the fastest growing segment of drug spend under the pharmacy benefit PBM Prime Therapeutics LLC reported that in 2013, specialty drugs expenses amount to 33.4% of total (pharmacy and medical) drug costs. If current trends continue, it will represent more than 50% by 2018.1 According to PhRMA, there are currently over 7,000 new medications in the biopharmaceutical pipeline 1 Prime Therapeutics LLC. 2013 drug trend insights. Available at: https://www.primetherapeutics.com/PDF/specialtydtr2013/index.html. Accessed January 2, 2014.
Slide 6-

Specialty Pharmacy Programs May include prior authorizations to ensure clinically appropriate and cost-effective use of treatments when certain criteria is met Incorporate evidence-based guidelines, dosing and discontinuation guidance, and monitoring Many specialty pharmacy providers have disease state management programs specific for conditions that are commonly treated with specialty pharmaceuticals
Slide 7-

Specialty Pharmacy Providers Specialty pharmacy is often a subset of retail pharmacy in managed care Payers often contract specifically with specialty pharmacies to provide specialty pharmaceutical services to their members Many payers own their own specialty pharmacy Cigna / Express Scripts – Cigna Specialty Pharmacy / Accredo Humana – Humana Specialty Pharmacy Caremark / Aetna – CVS Specialty Pharmacy / Aetna Specialty Pharmacy
Slide 8-

Components of Specialty Programs Refill reminders Delivery coordination Insurance verification Clinical interventions Patient education Adherence counseling Psychosocial assessment Patient assistance programs Integrated nursing staff
Slide 9-

Commonly Targeted Disease States Pulmonary arterial hypertension Multiple sclerosis Hepatitis C Rheumatoid arthritis Psoriasis RSV Oncology Blood disorders Cystic fibrosis Crohn’s disease Ulcerative Colitis Growth hormone deficiency Hemophilia HIV/AIDS Infertility
Slide 10-

Challenges in MCOs Billing systems- integration of medical and pharmacy claims Utilization management Drug coding- NDC vs. J code Benefit design and patient cost share Debbie Stern and Debi Reissman, “Specialty Pharmacy Cost Management Strategies of Private Health Care Payers,” Journal of Managed Care Pharmacy, November/December 2006. http://www.amcp.org/data/jmcp/Nov-Dec06JMCP1.pdf Accessed February 3, 2010
Slide 11-

Benefit Designs Cause of much confusion Medical benefit vs. pharmacy benefit Each MCO can design and deliver their own product and services Has led to additional formulary tiers Tier 4, Tier 5 and Tier 6 for example Traditionally associated with higher co-pays or co-insurances Many plans are moving towards new benefit designs for specialty drugs and therapies, including a “specialty formulary”
Slide 12-

Impact on Patients Specialty expenditures per member increased by 11.1% from 2004 to 2008 (in a 8 million member commercial plan) Potential impact of shifting costs to patients with specialty drugs: Inability or refusal to pay for medications leading to decreased compliance Compliance issues may impact medical expenses and hospital costs
Slide 13-

Monitoring for Adverse Reactions Prescription drug safety is key with specialty pharmaceuticals Problems arise when a drug offers significant therapeutic benefits but also carries challenging health or safety risks FDA Mandated Risk Evaluation and Mitigation Strategy (REMS) Many biologics and new therapies are subject to REMS Includes patient registries, ongoing patient monitoring, and certification for prescribers and pharmacies Specialty pharmacies have a high level of patient and physician interaction and specially trained therapy teams to assist with meeting these requirements
Slide 14-

Summary Specialty pharmacy is a growing part of the pharmacy industry Specialty pharmacy providers continue to develop programs and value-added services to better manage patients Payers continue to develop new strategies to manage the high costs of these drugs Patients are often affected by the variance in coverage and cost shares
Slide 15-

References Prime Therapeutics LLC. 2011 drug trend insights. 8/11. Available at: http://www.primetherapeutics.com/PDF/2011PrimeDrugTrendInsights.pdf. Accessed September 14,2011. Debbie Stern and Debi Reissman, “Specialty Pharmacy Cost Management Strategies of Private Health Care Payers,” Journal of Managed Care Pharmacy, November/December 2006. http://www.amcp.org/data/jmcp/Nov-Dec06JMCP1.pdf. Accessed February 3, 2010. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of Prescription Abandonment with Cost Share for High-Cost Specialty Pharmacy Medications. Journal of Managed Care Pharmacy 2009;15(8)648-58. Specialty pharmacy's role in REMS, FDA's new drug safety program. Formulary. 2009;44:300–308. FMCP Specialty Pharmacy Initiative: Phase I Discovery & U.S. Environmental Scan. October 2009. www.fmcpnet.org. Accessed February 1, 2010. The Biopharmaceutical Industry: Creating Research, Progress and Hope. http://www.phrma.org/about/biopharmaceutical_sector. Accessed February 1, 2015.
Slide 16-

Part 2: Biosimilars
Slide 17-

Biologics Price Competition and Innovation Act (BPCIA) Established in 2009 to create an abbreviated licensure pathway for biological products that are demonstrated to be “biosimilar” to or “interchangeable” with an FDA-licensed biological product.
Slide 18-

Biologic Marketplace Kozlowski, S et al. NEJM. 365(5); 385-88.
Slide 19-

Trend Towards Biologics
Slide 20-

Biologic Biologic: Therapeutic product derived from a biological source Vaccines Antitoxins Blood products Proteins Monoclonal antibodies www.fda.gov
Slide 21-

Biologics Vs. Small Molecules Biologics, including biosimilars are much more complex than small molecule drugs Small molecule drug Small biologic Large biologic COMPLEXITY
Slide 22-

Biosimilar Biosimilar Highly similar to the U.S. licensed reference biological product notwithstanding minor differences in clinically inactive components No clinically meaningful differences from the reverence product in terms of safety, purity, and potency www.fda.gov
Slide 23-

Interchangeable Interchangeable Biosimilar to the U.S. licensed reference product Expected to produce the same clinical result to the reference product in any given patient If a product is indicated for multiple administrations, then the product must be able to be alternated with the reference product without any loss of efficacy or change in risk of adverse events May be substituted at the pharmacy level without the intervention of a healthcare provider www.fda.gov
Slide 24-

Biosimilar 351(k) Application In order to be granted biosimilar status by the FDA, the biological product must show clinical data derived from: Analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; Animal studies (including the assessment of toxicity); and A clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
Slide 25-

Biosimilar 351(k) Application Stepwise Approach: Extensive structural and functional characterization of both products Animal data if contains pertinent information not able to be obtained from humans (e.g. toxicity) Human Pharmacokinetic studies Human Pharmacodynamic studies Compare clinical immunogenicity If inconsistencies exist, consider clinical trial with appropriate safety and efficacy measures http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf
Slide 26-

FDA Purple Book First published September 9, 2014 Lists biological products, including any biosimilar and interchangeable biological products licensed by the FDA under the Public Health Service Act (PHS Act) Includes the date a biological product was licensed under 351(a) of the PHS Act and whether the FDA evaluated the biological product for reference product exclusivity under section 351(k)(7) Shows if the FDA has determined a product to be biosimilar or interchangeable with an already licensed FDA reference biological product Biosimilar and interchangeable products are listed under the reference product
Slide 27-

Biosimilar: Filgrastim First application under the new biosimilar pathway brought to an FDA advisory committee On January 7th, 2015, the FDA Oncologic Drugs Advisory Committee unanimously voted that Sandoz’s EP2006 (Zarxio) should be licensed as biosimilar to the reference product, Neupogen Includes all 5 indications for which Neupogen is approved Zarxio (filgrastim-sndz) was approved March 6, 2015 as a biosimilar, not an interchangeable Route of administration, indications and side effects are the same as Neupogen Launched September 3, 2015 15 percent wholesale list price discount
Slide 28-

Biosimilar Naming Nonproprietary Naming of Biological Products Guidance finalized January, 2017 Per FDA Guidance biosimilars receive a nonproprietary name consisting of a common core plus a unique FDA-approved suffix composed of four lowercase letters For example, for products sharing the core name replicamab, those proper names may be displayed as: -replicamab-cznm -replicamab-hixf The proposed suffix should: Be unique Be devoid of meaning Be four lowercase letters of which at least three are distinct Be nonproprietary Be attached to the core name with a hyphen Be free of legal barriers that would restrict its usage www.fda.gov
Slide 29-

Outstanding Questions How much will the addition of biosimilars lower costs to the health care system? Will increased access to biologics lead to better health outcomes overall? How will managed care organizations manage these agents?
Slide 30-

References Information for Healthcare Professionals (Biosimilars). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm241719.htm. Accessed February 1st, 2015. "Biosimilars," Health Affairs, October 10, 2013. Accessed February 1st, 2015. Purple Book. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/ucm411418.htm. Accessed February 1st, 2015. Kate Traynor. FDA Advisers Recommend Approval of Biosimilar Filgrastim. http://www.ashp.org/menu/news/pharmacynews/newsarticle.aspx?id=4163. January 26th, 2015. Accessed February 1st, 2015.
Slide 31-

Thank you to AMCP member Jorge Farias for updating this presentation for 2016.
Slide 32-

To improve patient health by ensuring access to high-quality, cost-effective medications and other therapies. Mission & Vision

User Presentation
Related Presentations

Rare Diseases and the Orphan Drug Act in the US

By: MattB
Views: 2586

Managed Care Models: The Benefit vs. Cost Balance

By: MattB
Views: 1525

Cancer Medicines: Value in Context

By: MattB
Views: 2435

United Nations Office on Drugs and Crime (UNODC) World Drug Report 2020 - Booklet 4.5

By: MattB
Views: 2126

Evaluate Vantage Report on impact of COVID-19 Biopharma and Medtech

By: MattB
Views: 1424

Antidepressants

By: yara92
Views: 2674

Medication Decision Support Systems

By: Dashti
Views: 1202

About Pharmacoeconomics

By: medhelp
Views: 1332

Chronic Fatigue Syndrome

By: jasmescooper
Views: 1289

Assessing and Managing Medicine Safety

By: drdwayn
Views: 1865

MattB

About : An experienced pharma professional managing sales, marketing and brand management of top global pharma products Presently leading a team of experts in the development and execution of pharma eCommerce strategies that support GSK products to HCP customers.
Occupation : Medical Professional
Specialty : Other Health Professionals
Country : United States of America
Website :

HEALTH A TO Z